title: Efficacy of diuretics and beta-blockers in diabetic hypertensive patients. Results from a meta-analysis. The INDANA Steering Committee.
abstract: OBJECTIVE
  To review the effectiveness of diuretic or beta-blocker-based treatment of hypertension in diabetic patients.
  
  
  METHODS
  A meta-analysis on individual patient data was performed on four trials of the treatment of hypertension in which diabetic patients were included and treated with first-line diuretics or beta-blockers. The main outcomes were the relative risk of death, fatal or nonfatal stroke, fatal or nonfatal coronary events, and major cardiovascular events.
  
  
  RESULTS
  There were 92 diabetic patients who received first-line beta-blockers and 1,008 who received diuretics. In the control groups, diabetic patients had nearly twice the risk of any outcome when compared with nondiabetic patients. The same blood pressure reduction was achieved under treatment in the diabetic and nondiabetic patients, except for systolic pressure, which decreased more in the nondiabetic patients at 1 year. In the 15,843 nondiabetic patients, the risk of all four outcomes was reduced significantly in the treated group. In the 2,254 diabetic patients, the risk reduction was significant only for fatal and nonfatal stroke (36%, P = 0.011) and major cardiovascular events (20%, P = 0.032), but not for death (5%, P = 0.65) and fatal or nonfatal coronary events (15%, P = 0.23). However, no heterogeneity was detected between diabetic patients and nondiabetic patients for any outcome. The numbers of outcomes avoided for 1,000 patients treated for 5 years were higher in diabetic patients (e.g., 38 major cardiovascular events) than with nondiabetic patients (e.g., 28 major cardiovascular events).
  
  
  CONCLUSIONS
  These results show that hypertensive diabetic patients benefit from first-line treatment with diuretics. No conclusion can be drawn for beta-blockers, owing to the small sample size.
authors.affiliation: Clinical Pharmacology Department, Claude Bernard University (Equipe d'Accueil 643), Lyon Hospitals, France. michel.lievre@upcl.univ-lyon1.fr
authors.forename: M
authors.initials: M
authors.lastname: Lièvre
authors.forename: F
authors.initials: F
authors.lastname: Gueyffier
authors.forename: T
authors.initials: T
authors.lastname: Ekbom
authors.forename: R
authors.initials: R
authors.lastname: Fagard
authors.forename: J
authors.initials: J
authors.lastname: Cutler
authors.forename: E
authors.initials: E
authors.lastname: Schron
authors.forename: M
authors.initials: M
authors.lastname: Marre
authors.forename: J P
authors.initials: JP
authors.lastname: Boissel
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000368:Aged; D001794:Blood Pressure; D002318:Cardiovascular Diseases / Q000517:prevention & control; D003925:Diabetic Angiopathies / Q000188:drug therapy* / Q000401:mortality / Q000517:prevention & control; D004232:Diuretics / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D008875:Middle Aged; D009026:Mortality; D012307:Risk Factors; D020521:Stroke / Q000517:prevention & control; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D004232:Diuretics